Everence Capital Management Inc. trimmed its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Free Report) by 5 ...
This was the stock's third consecutive day of gains.
After years of controversy, stem cells are on the cusp of cures for conditions like epilepsy and type 1 diabetes.
NEW YORK, NY / ACCESSWIRE / January 3, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui.
The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...
NEW YORK, NY / ACCESSWIRE / January 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...
Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...
Zacks.com on MSN4d
Vertex Pharmaceuticals Incorporated (VRTX) is Attracting Investor Attention: Here is What You Should KnowVertex Pharmaceuticals (VRTX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...
Shares of Vertex Pharmaceuticals Inc. VRTX inched 0.84% higher to $402.70 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43 ...
The website you are visiting is protected and accelerated by Incapsula. Your computer may have been infected by malware and ...
Vertex Pharmaceuticals offers promising opportunities in pain management, cystic fibrosis treatments, and a diversified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback